local
83% of peptide-aware Americans want the FDA to make peptides more accessible
Summary by The El Paso Editorial Desk · Based on reporting by Stacker , KVIA ABC-7
· July 22, 2026
· 4 min read
Days before an FDA advisory committee meets to consider whether seven widely used peptides — BPC-157, TB-500, KPV, MOTS-c, Emideltide (DSIP), Semax, and Epitalon — should become eligible for compounding, a new survey suggests that’s what Americans want. Among 2,491 U.S. adults familiar with pepti...
Story provenance No corrections
Summary created by The El Paso Editorial Desk — automated, rule-governed Original reporting Stacker, KVIA ABC-7 Original story Read at the source Source published Jul 22, 2026 Indexed here Jul 22, 2026 AI assistance Automated summary drawn from the source’s own published text Prepublication human review No — editorial rules, flagged-item review, and published samples
Every story comes with a passport. How we work · Corrections log
Key takeaway adults familiar with peptides as a health and wellness tool surveyed by longevity care platform Hone Health in May 2026, 83% support allowing licensed compounding pharmacies to produce popular peptides with a physician’s prescription.
Why this matters
Local news anchors readers in their community — the people, places, and decisions that shape day-to-day life. The El Paso covers these stories because national outlets often won't.
About this story
Original reporting by KVIA ABC-7 . The El Paso surfaces reporting from trusted publishers and adds local editorial context so readers can quickly understand what a story means for their community. We attribute every source, link to the original report, and follow a documented editorial standards policy. To understand how stories are selected and reviewed, read our about page .
For the complete original report, visit KVIA ABC-7 . Have a tip or correction? Contact our newsroom .
Category: local ·
Published: July 22, 2026 ·
Source: KVIA ABC-7 ·
Reading time: 4 min
Frequently asked about this story
What is this story about? Days before an FDA advisory committee meets to consider whether seven widely used peptides — BPC-157, TB-500, KPV, MOTS-c, Emideltide (DSIP), Semax, and Epitalon — should become eligible for compounding, a new survey suggests that’s what Americans want. Among 2,491 U.S. adults familiar with pepti...
When was this published? This article was first published on July 22, 2026 by KVIA ABC-7 and curated for The El Paso readers.
Who reported this story? This story was reported by Stacker at KVIA ABC-7. To learn more about how The El Paso selects and reviews stories, see our editorial standards .
Where can I find related coverage? See more local coverage from The El Paso, or browse our daily briefing and topic hubs .
← Back to all news
More local →
Today’s briefing
Subscribe to newsletter